An International, Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Two Year Treatment With Teriflunomide 7 mg Once Daily and 14 mg Once Daily Versus Placebo in Patients With a First Clinical Episode Suggestive of Multiple Sclerosis Plus a Long Term Extension Period

Trial Profile

An International, Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Two Year Treatment With Teriflunomide 7 mg Once Daily and 14 mg Once Daily Versus Placebo in Patients With a First Clinical Episode Suggestive of Multiple Sclerosis Plus a Long Term Extension Period

Completed
Phase of Trial: Phase III

Latest Information Update: 28 Oct 2017

At a glance

  • Drugs Teriflunomide (Primary)
  • Indications Multiple sclerosis
  • Focus Registrational; Therapeutic Use
  • Acronyms TOPIC
  • Sponsors Sanofi
  • Most Recent Events

    • 28 Oct 2017 Results assessing the effect of cortical GM volume (CGMV) change on risk of conversion to CDMS in this trial, were presented at the 7th Joint Congress of the European Committee for Treatment and Research in Multiple Sclerosis and Americas Committee for Treatment and Research in Multiple Sclerosis.
    • 26 Oct 2017 Results from a post hoc analysis of this trial will be presented the 7th Joint Meeting of the European and Americas Committees for Research and Treatment in Multiple Sclerosis (ECTRIMS-ACTRIMS), as reported in a Sanofi Genzyme Media Release
    • 26 Oct 2017 Results of a post hoc analysis from core trial and extension portion published in the Sanofi Genzyme Media Release
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top